Evidence map›Paper›PMID 38279716›Full record

ArticleCentral nervous system agents in medicinal chemistry2024

Purple Carrot Extract Exhibits a Neuroprotective Profile in th e Nigrostriatal Pathway in the Reserpine-induced Model of Parkinson 's Disease.

Ana Claudia Custódio-Silva, Jose Ivo Araújo Beserra-Filho, Beatriz Soares-Silva, Amanda Maria-Macêdo, Suellen Silva-Martins, Sara Pereira Silva, José Ronaldo Santos, Regina Helena Silva, Daniel Araki Ribeiro, Alessandra Mussi Ribeiro

Abstract read
PubMed Publisher
In one paragraph

Article in Central nervous system agents in medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ana Claudia Custódio-SilvaDepartment of Biosciences, Universidade Federal de São Paulo, Santos, SP, Brazil.ORCID 0000-0002-6190-7672
Jose Ivo Araújo Beserra-FilhoDepartment of Biosciences, Universidade Federal de São Paulo, Santos, SP, Brazil.ORCID 0000-0003-3041-9446
Beatriz Soares-SilvaDepartment of Biosciences, Universidade Federal de São Paulo, Santos, SP, Brazil.ORCID 0000-0003-3577-2943
Amanda Maria-MacêdoDepartment of Biosciences, Universidade Federal de São Paulo, Santos, SP, Brazil.
Suellen Silva-MartinsDepartment of Biosciences, Universidade Federal de São Paulo, Santos, SP, Brazil.ORCID 0000-0001-5591-1096
Sara Pereira SilvaDepartment of Biosciences, Universidade Federal de São Paulo, Santos, SP, Brazil.ORCID 0000-0002-9189-8375
José Ronaldo SantosDepartment of Biosciences, Universidade Federal of Sergipe, Itabaiana, SE, Brazil.ORCID 0000-0001-9108-7532
Regina Helena SilvaDepartment of Pharmacology, Universidade Federal of São Paulo, São Paulo, SP, Brazil.ORCID 0000-0001-9017-3922
Daniel Araki RibeiroDepartment of Biosciences, Universidade Federal de São Paulo, Santos, SP, Brazil.ORCID 0000-0001-5057-4983
Alessandra Mussi RibeiroDepartment of Biosciences, Universidade Federal de São Paulo, Santos, SP, Brazil.ORCID 0000-0002-7697-5766
Universidade Federal de São Paulo · BRUniversidade Federal de Sergipe · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) #425694/2016-0, #408377/2021-6, #310403/2021-9Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) 001Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) #2015/20785-8, #2015/03354-3, #2020/09015-4, #2018/26609-5
6 · The paper itself

Abstract

backgroundParkinson's disease (PD) is a chronic neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the nigrostriatal pathway. Even with scientific and technological advances, the therapeutic approaches used for the treatment of PD have shown to be largely ineffective in controlling the progression of symptoms in the long term. There is a growing demand for the development of novel therapeutic strategies for PD treatment. Different herbs and supplements have been considered as adjuvant to treat the symptoms of Parkinsonism. The carrot is one of the most consumed vegetable species worldwide, and its root is known for its content of anthocyanins, which possess antioxidant and antiinflammatory properties. This study evaluated the neuroprotective effect of purple carrot extract (CAR) in rats on the reserpine (RES)-induced progressive parkinsonism model.

methodsMale rats (6-month-old) received orally the CAR (400 mg/kg) or vehicle and subcutaneously RES (0.01 mg/kg) or vehicle for 28 days (Preventive Phase). From the 29th day, rats received CAR or vehicle daily and RES (0.1 mg/kg) or vehicle every other day (for 23 days, Protective phase). Behavioral tests were conducted throughout the treatment. Upon completion, the animals' brain were processed for tyrosine hydroxylase (TH) immunohistochemical assessment.

resultsOur results showed that the chronic treatment of CAR protected against motor disabilities, reducing the time of catalepsy behavior and decreasing the frequency of oral movements, possibly by preserving TH levels in the Ventral Tegmental Area (VTA) and SNpc.

conclusionCAR extract is effective to attenuate motor symptoms in rats associated with increased TH+ levels in the Ventral Tegmental Area (VTA) and SNpc, indicating the potential nutraceutical benefits of CAR extract in a progressive parkinsonism model induced by RES.

Indexed as

Daucus carotaNeuroprotective AgentsPlant ExtractsReserpineTyrosine 3-MonooxygenaseAnimalsCorpus StriatumDisease Models, AnimalMaleRatsRats, WistarSubstantia NigraNeuroprotective AgentsPlant ExtractsReserpineTyrosine 3-Monooxygenasemotor behavior.Natural productsneurodegenerative diseaseneuroprotectionnutraceuticalsparkinson’s disease

Identifiers

PMID38279716
OpenAlexW4391253018

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.